US3741631036
© Globe Newswire
11.12.2025
GERN
LISTED
NASDAQ
Geron Corporation Announces Strategic Restructuring Plan to Position the Company for Long-Term Value Creation
News Preview
Restructuring Supports RYTELO® U.S. Commercial Strategy and Investment in Clinical Development...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
GERN
LISTED
NASDAQ
Geron Corporation Presents New Data at ASH 2025 Highlighting the Relationship Between Treatment-Emergent Cytopenias and Clinical Benefit of RYTELO® (Imetelstat) in Lower-Risk MDS
News Preview
Oral presentation from pooled analyses of the IMerge population suggests that treatment-emergent cytopenias may reflect on-target effects associated with meaningful clinical outcomes, including hemoglobin increases and transfusion independence in lower-risk MDS...
Themefolio
Profiler
Peergroup
© PR Newswire
04.12.2025
GERN
LISTED
NASDAQ
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points
News Preview
Issued on behalf of GT Biopharma, Inc.USA News Group News CommentaryVANCOUVER, BC, Dec. 4, 2025 /CNW/ -- Triple-therapy immunotherapy approaches are demonstrating complete leukemia elimination in preclinical models by reprogramming how cancer cells die to trigger powerful immune responses[1], while breakthrough natural killer cell research is reve...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© PR Newswire
04.12.2025
GERN
LISTED
NASDAQ
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points
News Preview
Issued on behalf of GT Biopharma, Inc.USA News Group News CommentaryVANCOUVER, BC, Dec. 4, 2025 /PRNewswire/ -- Triple-therapy immunotherapy approaches are demonstrating complete leukemia elimination in preclinical models by reprogramming how cancer cells die to trigger powerful immune responses[1], while breakthrough natural killer cell research...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
05.11.2025
GERN
LISTED
NASDAQ
Geron Corporation Reports Third Quarter 2025 Financial Results and Recent Business Highlights
News Preview
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial results for the third quarter of 2025 and recent business highlights.
"The high unmet need in lower-risk MDS is well known, and RYTELO is a therapy with a novel mechanism of action...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
GERN
LISTED
NASDAQ
Geron Corporation to Present at Upcoming Investor Conferences
News Preview
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that Harout Semerjian, Chief Executive Officer, is scheduled to present at the following investor conferences:
Stifel 2025 Healthcare Conference
Fireside chat on Tuesday, November 11 at 11...
Themefolio
Profiler
Peergroup
© BusinessWire
03.11.2025
GERN
LISTED
NASDAQ
Geron Corporation Announces Five Presentations Selected for ASH 2025 Highlighting Clinical Activity of RYTELO® (imetelstat) in Myeloid Hematologic Malignancies
News Preview
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that five abstracts – one oral and four poster presentations – have been accepted for presentation at the 67th American Society of Hematology (ASH) 2025 Annual Meeting, to be held December 6-...
Themefolio
Profiler
Peergroup
© BusinessWire
27.10.2025
GERN
LISTED
NASDAQ
Geron Plans to Announce Third Quarter 2025 Financial Results on November 5, 2025
News Preview
Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company aiming to change lives by changing the course of cancer, today announced that it will release its third quarter financial results and business highlights before the market opens on Wednesday, November 5, 2025 via press release, which will be available on the Company’s w...
Themefolio
Profiler
Peergroup
© BusinessWire
20.10.2025
GERN
LISTED
NASDAQ
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards on (i) October 17, 2025, covering an aggregate of 1,579,500 shares of its common stock, consisting of stock options to purchase an aggregate of 1,553,000 shares of common stock, and restricted stock units (“RSUs”) repres...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.10.2025
GERN
LISTED
NASDAQ
Geron Corporation Announces Executive Leadership Transitions and Appointments
News Preview
Four new executives appointed, including new Chief Commercial Officer, to lead commercial strategy and operations Four new executives appointed, including new Chief Commercial Officer, to lead commercial strategy and operations...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.09.2025
GERN
LISTED
NASDAQ
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
FOSTER CITY, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 966,000 shares of its common stock, consisting of stock options to purchase an aggregate of 644,000 shares of common stock, and restricted...
Themefolio
Profiler
Peergroup
© BusinessWire
27.08.2025
GERN
LISTED
NASDAQ
Geron to Participate in the 2025 Wells Fargo Healthcare Conference
News Preview
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that management is scheduled to participate in a fireside chat on September 4, 2025 at the 2025 Wells Fargo Healthcare Conference in Boston, MA.
A live webcast of the presentation will be available at ir.geron.com and will be posted on the Investors a...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
18.08.2025
GERN
LISTED
NASDAQ
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 522,000 shares of its common stock, consisting of stock options to purchase an aggregate of 348,000 shares of common stock, and restricted stock units (“RSUs”) representing an aggregate of 174,00...
Themefolio
Profiler
Peergroup
© BusinessWire
28.07.2025
GERN
LISTED
NASDAQ
Geron Plans to Announce Second Quarter 2025 Financial Results on August 6, 2025
News Preview
Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today announced that it will release its second quarter financial results and business highlights before the market opens on Wednesday, August 6, 2025 via press release, which will be available on the Company’s website at www.geron.com/investors. Geron will host a conf...
Themefolio
Profiler
Peergroup
© BusinessWire
18.07.2025
GERN
LISTED
NASDAQ
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 342,000 shares of its common stock, consisting of stock options to purchase an aggregate of 228,000 shares of common stock, and restricted stock units (“RSUs”) representing an aggregate of 114,00...
Themefolio
Profiler
Peergroup
© BusinessWire
18.06.2025
GERN
LISTED
NASDAQ
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 1,116,000 shares of its common stock, consisting of stock options to purchase an aggregate of 744,000 shares of common stock, and restricted stock units (“RSUs”) representing an aggregate of 372,...
Themefolio
Profiler
Peergroup
© BusinessWire
28.05.2025
GERN
LISTED
NASDAQ
Geron Announces Presentations at ASCO and EHA Underscoring RYTELO® (imetelstat) Efficacy and Safety Across Range of LR-MDS Patients, and Showcasing Momentum of Myelofibrosis Program
News Preview
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced presentations on RYTELO® (imetelstat) at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2025 Congress. Together, the presen...
Themefolio
Profiler
Peergroup
© BusinessWire
19.05.2025
GERN
LISTED
NASDAQ
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 411,000 shares of its common stock, consisting of stock options to purchase an aggregate of 274,000 shares of common stock, and restricted stock units (“RSUs”) representing an aggregate of 137,00...
Themefolio
Profiler
Peergroup
© BusinessWire
12.05.2025
GERN
LISTED
NASDAQ
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Geron
News Preview
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Geron Corporation (“Geron” or the “Company”) (NASDAQ: GERN) and reminds investors of the May 12, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi & Far...
Themefolio
Profiler
Peergroup
© BusinessWire
09.05.2025
GERN
LISTED
NASDAQ
GERN Investors Have Opportunity to Join Geron Corporation Fraud Investigation with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Geron Corporation (“Geron” or “the Company”) (NASDAQ: GERN) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to discl...
Themefolio
Profiler
Peergroup
© BusinessWire
07.05.2025
GERN
LISTED
NASDAQ
Geron Corporation Reports First Quarter 2025 Financial Results and Recent Business Highlights
News Preview
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial results for the first quarter of 2025 and recent business highlights.
"We are confident in the long-term potential of RYTELO as an important therapeutic for eligible patients with l...
Themefolio
Profiler
Peergroup
© BusinessWire
06.05.2025
GERN
LISTED
NASDAQ
Kirby McInerney LLP Urges Investors in Geron Corporation (GERN) to Inquire About Their Rights in Class Action Lawsuit
News Preview
The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Northern District of California on behalf of those who acquired Geron Corporation (“Geron” or the “Company”) (NASDAQ:GERN) securities during the period from June 7, 2024, through February 25, 2025 (“the Class Period”)...
Themefolio
Profiler
Peergroup
© BusinessWire
27.04.2025
GERN
LISTED
NASDAQ
GERN Deadline: Rosen Law Firm Urges Geron Corporation (NASDAQ: GERN) Stockholders to Contact the Firm for Information About Their Rights
News Preview
Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers and acquirers of Geron Corporation (NASDAQ: GERN) securities between February 28, 2024 and February 25, 2025. Geron is a commercial-stage biopharmaceutical company.
For more information, submit a form, email attorne...
Themefolio
Profiler
Peergroup
© BusinessWire
27.04.2025
GERN
LISTED
NASDAQ
Lead Plaintiff Deadline on May 12, 2025 for GERN Investors - Kessler Topaz Meltzer & Check, LLP Encourages Investors with Losses to Contact the Firm
News Preview
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that securities class action lawsuits have been filed against Geron Corporation (“Geron”) (NASDAQ: GERN) on behalf of those who purchased or otherwise acquired Geron securities between February 28, 2024, and February 25, 2025, inclusive (the “Class Period”). Th...
Themefolio
Profiler
Peergroup
© BusinessWire
18.04.2025
GERN
LISTED
NASDAQ
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 1,551,000 shares of its common stock, consisting of stock options to purchase an aggregate of 1,034,000 shares of common stock and restricted stock units (“RSUs”) representing an aggregate of 517...
Themefolio
Profiler
Peergroup
© BusinessWire
31.03.2025
GERN
LISTED
NASDAQ
Geron Plans to Announce First Quarter 2025 Financial Results on May 7, 2025
News Preview
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that it will release its first quarter financial results and business highlights before the market opens on Wednesday, May 7, 2025 via press release, which will be available on the Company’s website at www.geron.com/investors. Geron will host a conferen...
Themefolio
Profiler
Peergroup
© BusinessWire
28.03.2025
GERN
LISTED
NASDAQ
GERN Investors Have Opportunity to Lead Geron Corporation Securities Fraud Lawsuit with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Geron Corporation (“Geron” or “the Company”) (NASDAQ: GERN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investo...
Themefolio
Profiler
Peergroup
© BusinessWire
26.03.2025
GERN
LISTED
NASDAQ
GERN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Geron Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
News Preview
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Geron Corporation (“Geron” or “the Company”) (NASDAQ: GERN) and certain of its officers.
Class Definition
This lawsuit seeks to recover damages against Defendants for alleged violat...
Themefolio
Profiler
Peergroup
© BusinessWire
26.03.2025
GERN
LISTED
NASDAQ
GERN Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against Geron Corporation (GERN) - Contact Kessler Topaz Meltzer & Check, LLP
News Preview
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that securities class action lawsuits have been filed against Geron Corporation (“Geron”) (NASDAQ: GERN) on behalf of those who purchased or otherwise acquired Geron securities between February 28, 2024, and February 25, 2025, inclusive (the “Class Period”). Th...
Themefolio
Profiler
Peergroup
© BusinessWire
20.03.2025
GERN
LISTED
NASDAQ
GERN ALERT: Kirby McInerney LLP Reminds Geron Corporation Investors of Securities Class Action
News Preview
The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Northern District of California on behalf of those who acquired Geron Corporation (“Geron” or the “Company”) (NASDAQ: GERN) securities during the period from June 7, 2024, through February 25, 2025 (“the Class Period”...
Themefolio
Profiler
Peergroup
© BusinessWire
19.03.2025
GERN
LISTED
NASDAQ
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 225,000 shares of its common stock, consisting of stock options to purchase an aggregate of 150,000 shares of common stock and restricted stock units (“RSUs”) representing an aggregate of 75,000...
Themefolio
Profiler
Peergroup
© BusinessWire
19.03.2025
GERN
LISTED
NASDAQ
GERN INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Geron Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
News Preview
Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Geron Corporation (NASDAQ: GERN) securities between February 28, 2024 and February 25, 2025, both dates inclusive (the “Class Period”), have until May 12, 2025 to seek appointment as lead plaintiff of the Geron class action lawsuit. Captioned Dabestani v. Geron Corporat...
Themefolio
Profiler
Peergroup
© BusinessWire
18.03.2025
GERN
LISTED
NASDAQ
GERN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Geron Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
News Preview
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Geron Corporation (“Geron” or “the Company”) (NASDAQ: GERN) and certain of its officers.
Class Definition
This lawsuit seeks to recover damages against Defendants for alleged violat...
Themefolio
Profiler
Peergroup
© BusinessWire
15.03.2025
GERN
LISTED
NASDAQ
GERN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Geron Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
News Preview
The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Geron Corporation (NASDAQ: GERN) securities between February 28, 2024 and February 25, 2025, both dates inclusive (the “Class Period”), have until May 12, 2025 to seek appointment as lead plaintiff of the Geron class action lawsuit. Captioned Dabestani v...
Themefolio
Profiler
Peergroup
© BusinessWire
15.03.2025
GERN
LISTED
NASDAQ
GERN Investors Have Opportunity to Lead Geron Corporation Securities Fraud Lawsuit with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Geron Corporation (“Geron” or “the Company”) (NASDAQ: GERN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investo...
Themefolio
Profiler
Peergroup
© BusinessWire
14.03.2025
GERN
LISTED
NASDAQ
Rosen Law Firm Urges Geron Corporation (NASDAQ: GERN) Stockholders to Contact the Firm for Information About Their Rights
News Preview
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers and acquirers of Geron Corporation (NASDAQ: GERN) securities between June 7, 2024 and February 25, 2025, both dates inclusive (the “Class Period”). Geron is a commercial-stage biopharmaceutical company.
For more information...
Themefolio
Profiler
Peergroup
© BusinessWire
11.03.2025
GERN
LISTED
NASDAQ
Geron Announces European Commission Approval of RYTELO® (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adults With Transfusion-Dependent Anemia Due to Lower-Risk MDS
News Preview
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that the European Commission (EC) has granted marketing authorization for RYTELO® (imetelstat) as a monotherapy for the treatment of adult patients with transfusion-dependent (TD) anemia due...
Themefolio
Profiler
Peergroup
© BusinessWire
11.03.2025
GERN
LISTED
NASDAQ
Geron Corporation Announces Departure of Chief Executive Officer
News Preview
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that John “Chip” A. Scarlett, M.D., President, Chief Executive Officer and Chairman, will depart the company on March 31, 2025. While a search for a new Chief Executive Officer with significa...
Themefolio
Profiler
Peergroup
© BusinessWire
26.02.2025
GERN
LISTED
NASDAQ
Geron Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
News Preview
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial results for the fourth quarter and full year 2024 and recent business highlights.
"2024 was a terrific year for Geron and for RYTELO, our first-in-class telomerase inhibitor, which...
Themefolio
Profiler
Peergroup
© BusinessWire
21.02.2025
GERN
LISTED
NASDAQ
Geron to Participate at Upcoming Investor Conferences in March 2025
News Preview
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that members of the management team are scheduled to participate in fireside chats at the following investor conferences:
TD Cowen 45th Annual Health Care Conference
Monday, March 3rd at 3:10pm ET (Boston, MA)
Leerink Global Healthcare Conference...
Themefolio
Profiler
Peergroup
© BusinessWire
19.02.2025
GERN
LISTED
NASDAQ
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 180,000 shares of its common stock, consisting of stock options to purchase an aggregate of 120,000 shares of common stock and restricted stock units (“RSUs”) representing an aggregate of 60,000...
Themefolio
Profiler
Peergroup
© BusinessWire
03.02.2025
GERN
LISTED
NASDAQ
Geron to Announce Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025
News Preview
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that it will release its fourth quarter and full-year 2024 financial results and business highlights before the market opens on Wednesday, February 26, 2025 via press release, which will be available on the Company’s website at www.geron.com/investors....
Themefolio
Profiler
Peergroup
© BusinessWire
21.01.2025
GERN
LISTED
NASDAQ
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 312,000 shares of its common stock, consisting of stock options to purchase an aggregate of 208,000 shares of common stock and restricted stock units (“RSUs”) representing an aggregate of 104,000...
Themefolio
Profiler
Peergroup
© BusinessWire
19.12.2024
GERN
LISTED
NASDAQ
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 72,000 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
The stock options were granted on De...
Themefolio
Profiler
Peergroup
© BusinessWire
13.12.2024
GERN
LISTED
NASDAQ
Geron Announces Positive CHMP Opinion for RYTELO™ (imetelstat) for the Treatment of Adults with Transfusion-Dependent Anemia due to Lower-Risk MDS
News Preview
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the approval of RYTELO (imetelstat) for the t...
Themefolio
Profiler
Peergroup
© BusinessWire
10.12.2024
GERN
LISTED
NASDAQ
Geron Announces New IMerge Analyses Presented at ASH Suggesting Clinical Activity of RYTELO™ (imetelstat) in Patients with Lower-Risk MDS Regardless of Type or Number of Prior Therapies
News Preview
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced new analyses presented at the 66th American Society of Hematology (ASH) Annual Meeting from the IMerge clinical trial in patients with lower-risk myelodysplastic syndromes (LR-MDS) with trans...
Themefolio
Profiler
Peergroup
© BusinessWire
10.12.2024
GERN
LISTED
NASDAQ
Geron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO™ (imetelstat) in Combination with Ruxolitinib as Frontline Therapy in Patients with Myelofibrosis
News Preview
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced results from an oral presentation at the 66th American Society of Hematology (ASH) Annual Meeting, reporting Phase 1 findings from the two-part IMproveMF study. The safety results from the do...
Themefolio
Profiler
Peergroup
© BusinessWire
27.11.2024
GERN
LISTED
NASDAQ
Geron to Participate in the 7th Annual Evercore ISI HealthCONx Conference
News Preview
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that members of the management team are scheduled to participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference, in Coral Gables, Florida on Wednesday, December 4, 2024, at 8:20 a.m. ET.
A webcast of the fireside chat will be...
Themefolio
Profiler
Peergroup
© BusinessWire
21.11.2024
GERN
LISTED
NASDAQ
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 1,017,000 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
The stock options were granted on...
Themefolio
Profiler
Peergroup
© BusinessWire
11.11.2024
GERN
LISTED
NASDAQ
Geron Corporation Announces Appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development
News Preview
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced the appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development, effective today, November 11, 2024. In this role, Dr. Eid will lead our Research and Development org...
Themefolio
Profiler
Peergroup
© BusinessWire
11.11.2024
GERN
LISTED
NASDAQ
Geron to Participate in the Stifel 2024 Healthcare Conference
News Preview
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced members of the management team are scheduled to participate in a fireside chat at the Stifel 2024 Healthcare Conference, in New York City, on Monday, November 18th, 2024, at 1:50pm ET.
A webcast of the fireside chat will be available through the Invest...
Themefolio
Profiler
Peergroup
© BusinessWire
07.11.2024
GERN
LISTED
NASDAQ
Geron Corporation Announces Up to $375 Million in Funding with Royalty Pharma and Pharmakon Advisors
News Preview
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced up to $375 million in synthetic royalty and debt financings with Royalty Pharma and investment funds managed by Pharmakon Advisors, LP, of which $250 million in cash was provided at closing a...
Themefolio
Profiler
Peergroup
© BusinessWire
07.11.2024
GERN
LISTED
NASDAQ
Geron Corporation Reports Third Quarter 2024 Financial Results and Recent Business Highlights
News Preview
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial results for the third quarter of 2024 and recent business highlights.
“This has been a transformative year for Geron, following our first FDA approval and commercial launch of RYTEL...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2024
GERN
LISTED
NASDAQ
Geron Announces New Data to be Presented at Upcoming ASH Annual Meeting Highlighting the Potential of RYTELO™ (imetelstat) in Myeloid Hematologic Malignancies
News Preview
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced the publication of abstracts containing new data highlighting the potential of RYTELO™ (imetelstat), a first-in-class telomerase inhibitor, in myeloid hematologic malignancies. Six abstracts...
Themefolio
Profiler
Peergroup
© BusinessWire
17.10.2024
GERN
LISTED
NASDAQ
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 680,220 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
The stock options were granted on Oc...
Themefolio
Profiler
Peergroup
© BusinessWire
15.10.2024
GERN
LISTED
NASDAQ
Geron to Announce Third Quarter 2024 Financial Results on November 7, 2024
News Preview
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that it will release its third quarter 2024 financial results and business highlights before the market opens on Thursday, November 7, 2024 via press release, which will be available on the Company’s website at www.geron.com/investors. Geron will host a...
Themefolio
Profiler
Peergroup
© BusinessWire
19.09.2024
GERN
LISTED
NASDAQ
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 500,220 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
The stock options were granted on Se...
Themefolio
Profiler
Peergroup
© BusinessWire
09.09.2024
GERN
LISTED
NASDAQ
Geron Corporation Announces Appointment of Jim Ziegler as Chief Commercial Officer
News Preview
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, announced the appointment of Jim Ziegler as Executive Vice President, Chief Commercial Officer, effective today, September 9, 2024. In this role, Mr. Ziegler will spearhead Geron’s global commercial strategy...
Themefolio
Profiler
Peergroup
© BusinessWire
22.08.2024
GERN
LISTED
NASDAQ
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 261,000 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
The stock options were granted on A...
Themefolio
Profiler
Peergroup
© Newsfile
06.03.2020
GERN
LISTED
NASDAQ
Geron Deadline Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Geron Corporation To Contact The Firm
News Preview
New York, New York--(Newsfile Corp. - March 6, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Geron Corporation (NASDAQ: GERN) ("Geron" or the "Company") of the March 23, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Far...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
